5 Key Takeaways

• 1

  A 3D-genomic blood test identified ME/CFS patients with 96% accuracy in an independent validation cohort.

• 2

  The EpiSwitch CFS test achieved 92% sensitivity and 98% specificity in distinguishing ME/CFS patients from healthy controls.

• 3

  The study analyzed whole-blood DNA from 47 severe housebound ME/CFS cases and 61 controls for initial profiling.

• 4

  Researchers noted the modest sample size and single-country cohort limited generalizability, necessitating larger studies.

• 5

  The study was approved by the UK National Research Ethics Service, and all participants provided written informed consent.